Cardiff Oncology, Inc. (CRDF) — 애널리스트 전망 / 애널리스트 컨센서스 목표가는. 기준 12 애널리스트 평가, 컨센서스는 강세 — 8 매수, 3 보유, 1 매도.
애널리스트 추정 주당순이익(EPS) $-0.99 및 매출 $0.00B 다음 회계연도.
주당순이익(EPS) 실적 추이: 2024: 실적 $-0.95 vs 추정 $-0.99 (상회 +3.9%). 2025: 실적 $-0.69 vs 추정 $-0.77 (상회 +10.2%). 애널리스트 정확도: 92%.
CRDF 애널리스트 등급
Buy
최근 3개월 동안 Cardiff Oncology, Inc.에 주식 등급을 부여한 12명의 애널리스트 기준
EPS 전망 — CRDF
92%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.95
vs Est –$0.99
▲ 4.0% off
2025
Actual –$0.69
vs Est –$0.77
▲ 11.3% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
매출 전망 — CRDF
84%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.001B
vs Est $0.001B
▲ 8.6% off
2025
Actual $0.001B
vs Est $0.000B
▲ 23.3% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
